Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease Therapy

Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease Therapy

Sidley represented Changchun GeneScience (GenSci) Pharmaceuticals, a China-based biotechnology company, in its exclusive out-license transaction with Yarrow Bioscience, a U.S.-based biotechnology company backed by RTW Investors, for the ex-China rights to a potential first-in-class antibody therapy for the treatment of Graves’ disease and thyroid eye disease. The transaction includes an upfront payment of US$70 million, US$50 million in near-ter…